未登录
分享
收藏
分享
收藏Neuromelanin and T2*-MRI for the assessment of genetically at-risk, prodromal, and symptomatic Parkinson's disease
Ben Bashat, Dafna; Thaler, Avner; Shacham, Hedva Lerman; Even-Sapir, Einat; Hutchison, Matthew; Evans, Karleyton C.; Orr-Urterger, Avi; Cedarbaum, Jesse M.; Droby, Amgad; Giladi, Nir; Mirelman, Anat; Artzi, Moran
分享
收藏
分享
收藏
分享
收藏
分享
收藏[18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies
Cohen, Dan; Luttwak, Efrat; Beyar-Katz, Ofrat; Krauthammer, Shir Hazut; Bar-On, Yael; Amit, Odelia; Gold, Ronit; Perry, Chava; Avivi, Irit; Ram, Ron; Even-Sapir, Einat
分享
收藏
分享
收藏
分享
收藏Preoperative 68Ga-PSMA PET/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection
Dekalo, Snir; Kuten, Jonathan; Mintz, Ishai; Fahoum, Ibrahim; Gitstein, Gilad; Keizman, Daniel; Sarid, David; Matzkin, Haim; Mabjeesh, Nicola J.; Beri, Avi; Even-Sapir, Einat; Yossepowitch, Ofer; Mano, Roy
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏Head-to-Head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard
Kuten, Jonathan; Fahoum, Ibrahim; Savin, Ziv; Shamni, Ofer; Gitstein, Gilad; Hershkovitz, Dov; Mabjeesh, Nicola J.; Yossepowitch, Ofer; Mishani, Eyal; Even-Sapir, Einat
分享
收藏
分享
收藏
分享
收藏FDG PET Parkinson's disease-related pattern as a biomarker for clinical trials in early stage disease
Matthews, Dawn C.; Lerman, Hedva; Lukic, Ana; Andrews, Randolph D.; Mirelman, Anat; Wernick, Miles N.; Giladi, Nir; Strother, Stephen C.; Evans, Karleyton C.; Cedarbaum, Jesse M.; Even-Sapir, Einat
分享
收藏
分享
收藏
分享
收藏